Perelman School of Medicine at the University of Pennsylvania
test_header

The Department of Radiation Oncology is in the new Perelman Center. Occupying approximately 80,000 square feet on the Concourse Level, the new treatment facilities includes the most advanced proton and conventional radiation treatment modalities available as well as public spaces designed for the highest levels of patient comfort.


About SARRP

SARRP Research Platform Advantages

  • Provides state-of-the-art 3D volumetric image guidance for localization and targeting of
    the dose
  • Conformal dose minimizes exposure to non-targeted tissues and organs
  • Non-invasive procedure
  • Easy to use, reliable, and reproducible
  • Customizable to meet new and innovative applications
  • High resolution, low imaging dose, on board CT imaging and 3D reconstruction
  • Image fusion options for easy target localization and avoidance of organs at risk
  • High precision beam geometry to achieve conformal dose distributions
  • Open platform to enable the addition of other imaging modalities for future research

SARRP System Features

  • Isocenter accuracy to 0.25 mm
  • On board cone beam CT and image reconstruction
  • Minimum field size of 0.5 mm diameter
  • Gantry and robotic specimen stage enable non-coplanar field arrangements

Applications

The SARRP research platform enables researchers to replicate the radiotherapy process of
imaging, target localization and radiotherapy treatment delivery techniques employed when
treating patients in clinical oncology departments. In order to improve the efficiency of radiation
therapy and minimize the short and long term side effects of cancer treatment it is vital to study
radiation biology using in vivo models.

  • Radiobiology
  • Pre clinical studies
  • DNA damage response
  • Tumor biology and the micro-environment
  • Bystander effects
  • Radiosensitizers
  • Cardiovascular toxicity
  • Oncology research
  • Preclinical validation of radiotherapy – assessing the risks of radiation exposure
    are balanced against the efficacy of the treatment in controlling and eliminating
    tumors
    • Normal tissue injury by radiotherapy
    • Immunology disease
    • Cardiovascular diseases
    • Radiobiological effectiveness
  • Characterize tumors that may not respond to ionizing radiation
  • DNA damage response
  • Can couple spatially targeted radiotherapy with molecularly targeted therapies to
    optimize treatments for solid tumors
  • Mechanism of tumor control


© The Trustees of the University of Pennsylvania || Site best viewed in a supported browser. || Site Design: PMACS Web Team